A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314Phase 3Recruiting
- Lead sponsor
- Akero Therapeutics, Inc (Industry)
- Enrollment
- 2,150 (estimated)
- Start date
- 4 Oct 2024
- Primary completion
- Feb 2030 (estimated)
- Study completion
- 1 Mar 2030
- Last update posted
- 13 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Efruxifermin Drug
- Placebo Drug
Conditions and primary outcome
- NASH - Nonalcoholic Steatohepatitis
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Primary outcome
Time from randomization to the first significant clinical event including disease progression, liver decompensation events, etc. (5 years); Cohort 1 only: Proportion of subjects with ≥ 1 stage improvement in fibrosis and no worsening of steatohepatitis (96 Weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06528314.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06528314 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.